Literature DB >> 9564457

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

J G Bartlett1, R F Breiman, L A Mandell, T M File.   

Abstract

This is part of the series of practice guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee. The purpose of this guideline is to provide assistance to clinicians in the diagnosis and treatment of community-acquired pneumonia. The targeted providers are internists and family practitioners. The targeted groups are immunocompetent adult patients. Criteria are specified for determining whether the inpatient or outpatient setting is appropriate for treatment. Differences from other guidelines written on this topic include use of laboratory criteria for diagnosis and approach to antimicrobial therapy. Panel members and consultants are experts in adult infectious diseases. The guidelines are evidence based where possible. A standard ranking system is used for the strength of the recommendations and the quality of the evidence cited in the literature reviewed. The document has been subjected to external review by peer reviewers as well as by the Practice Guidelines Committee and was approved by the IDSA Council. An executive summary and tables highlight the major recommendations. The guidelines will be listed on the IDSA home page at http://www.idsociety.org.

Entities:  

Mesh:

Year:  1998        PMID: 9564457     DOI: 10.1086/513953

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  155 in total

Review 1.  Quinolones: which generation for which microbe?

Authors:  M K Lee; M S Kanatani
Journal:  West J Med       Date:  1999-06

Review 2.  Diagnosis of pneumonia and monitoring of infection eradication.

Authors:  M Ruiz; C Arosio; P Salman; T T Bauer; A Torres
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 3.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

4.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

5.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.

Authors:  D Hardy; D Amsterdam; L A Mandell; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Use of an oxacillin disk screening test for detection of penicillin- and ceftriaxone-resistant pneumococci.

Authors:  L P Jetté; C Sinave
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

9.  Anaerobic Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

10.  Rehabilitation and Recovery After Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.